At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 88 enrolled
Drug / intervention
Interleukin 28B testingother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Cross-sectional Multicenter Study Evaluating the IL28B Polymorphism in Patients With HBeAg-negative Chronic Hepatitis B Treated With Pegylated Interferon Alfa-2a in the Course of Peg.Be.Liver Study
In Brief
A Phase 3 clinical trial evaluating Interleukin 28B testing for Hepatitis B, Chronic. Completed, enrolled 88 participants across 12 sites.
Detailed Summary
This cross-sectional multicenter study will evaluate the IL28B polymorphism in patients with HBeAg-negative chronic hepatitis B treated with Pegasys (peginterferon alfa-2a) in the predecessor ML18253 study. The study consists of a single visit where eligible patients will undergo a blood test for IL28B genotyping, with a phone follow-up 7 days after the visit.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis B, Chronic
CountriesItaly
Collaborators--
Timeline
Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedOct 2012
Enrollment StartNov 2012
Primary CompletionJun 2013
TodayJul 2026
First PostedOct 2, 2012
Enrollment StartNov 8, 2012
Primary CompletionJun 21, 2013
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 13.8 years ago
Interventions
Interleukin 28B testingother
Blood sampling for IL28B genotyping